NCT06222892

A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age

A Phase 1, Open-label Study to Investigate the Pharmacokinetics and Safety of Camlipixant in Male and Female Participants Aged 18-75 Years of Age With Hepatic Impairment Compared to Matched Healthy Participants With Normal Hepatic Function

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Bellus Health Inc. - a GSK company · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the effect of Hepatic impairment (HI) on the Pharmacokinetic (PK) profile and safety of Camlipixant.

Conditions

• Cough

Interventions

Type	Name	Description
DRUG	Camlipixant	Camlipixant was administered.

Timeline

• Start date: 2024-02-02
• Primary completion: 2024-12-17
• Completion: 2024-12-30
• First posted: 2024-01-25
• Last updated: 2026-01-07
• Results posted: 2026-01-07

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study